Statin induced myopathy

@article{Sathasivam2008StatinIM,
  title={Statin induced myopathy},
  author={Sivakumar Sathasivam and Bryan R F Lecky},
  journal={BMJ : British Medical Journal},
  year={2008},
  volume={337}
}
Since their introduction for the treatment of hypercholesterolaemia in 1987, the use of statins has grown to over 100 million prescriptions per year.1 About 1.5-3% of statin users in randomised controlled trials and up to 10-13% of participants enrolled in prospective clinical studies develop myalgia.1 2 3 4 As a conservative estimate, at least 1.5 million people per year will experience a muscle related adverse event while taking a statin. In this review we discuss statin induced myopathy and… 
Managing statin-induced myopathy.
TLDR
It is found that fatal rhabdomyolysis occurred in patients taking cerivastatin at a higher rate than that seen with other statins, prompting the drug’s withdrawal from the market in 2001.
Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?
TLDR
The need for international attention to address this important, but largely neglected clinical problem, that if unresolved will remain an impediment to the effective prevention and treatment of CVD is urged.
Management of statin myopathy
TLDR
This interesting review of statin-induced myopathy (SIM) with curcumin with concerns is supplemented by considerations, and several options are available to manage the clinical manifestations of SIM.
Statin-induced myopathy – a challenge for patients and physicians
TLDR
The types of statin-induced myopathy, the patient cohorts susceptible of developing this side effect and the treatment strategies for hypercholesterolemia/ dyslipidemia are showcased.
Statin use and myopathy. Not always guilty.
TLDR
Not all patients taking statins who develop muscle complaints have statin-related myopathy, and a thorough clinical evaluation and appropriate testing is warranted to avoid an unnecessary increase in cardiovascular risk.
Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture.
TLDR
In each patient with rhabdomyolysis, at least one polymorphism of "statins´ genes" was present, and in the group of patients treated by rosuvastatin, it was discovered not one case of rhabdomsolysis.
Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture.
TLDR
In the group of patients treated by rosuvastatin, it was discovered not one case of rhabdomyolysis and any occurrence of genetic polymorphisms of "statins´ genes" was present.
Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors
TLDR
A case of myalgia with elevated serum creatinine phosphokinase in a patient after 2 months of therapy with fixed dose combination of atorvastatin and ezetimibe (10 mg each).
Statin-Induced Autoimmune Necrotizing Myopathy
TLDR
A 73-year-old female presented to clinic with myalgia and fatigue and underwent an autoimmune workup which was positive for HMG-CoA reductase antibodies, and methotrexate 15 mg/week was initiated.
Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy
TLDR
The identification of patients with an increased proclivity to statin-induced myopathy could allow more cost-effective approaches of monitoring and screening, facilitate targeted prevention of potential complications, and further improve the already overwhelmingly positive benefit-risk ratio of statins.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study
TLDR
It is concluded that use of lipid-lowering drugs is associated with a substantially greater risk of myopathy, which is most pronounced for fibrates.
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis
TLDR
It is important to maintain perspective by looking at the impact of statin myopathy relative to the impactOf preventing atherosclerotic complications, the potential benefits of therapy must outweigh the risks and the benefit/risk ratio is overwhelmingly positive.
A Neuromuscular Approach to Statin-Related Myotoxicity
  • S. Baker, I. Samjoo
  • Medicine, Biology
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 2008
TLDR
A clinical management algorithm is presented which outlines a variety of co-morbidities which can potentiate the adverse effects of statins on muscle and a rational approach to the selection of those patients most likely to benefit from skeletal muscle biopsy is discussed.
Statin-induced apoptosis and skeletal myopathy.
TLDR
The mitochondrion is considered a regulatory center of apoptosis, and therefore its role in the induction of apoptotic activity will be discussed as well as the mechanism of statin-induced apoptosis and myopathy.
Genetic risk factors associated with lipid‐lowering drug‐induced myopathies
TLDR
A higher prevalence of underlying metabolic muscle diseases than expected in the general population is reported and the effect of statins on energy metabolism combined with a genetic susceptibility to triggering of muscle symptoms may account for myopathic outcomes in certain high‐risk groups.
Statin-Associated Myopathy with Normal Creatine Kinase Levels
TLDR
It appears that muscle symptoms of some patients receiving statin therapy might represent a muscle toxicity below the threshold needed to increase creatine kinase levels, which could rule out statin-associated myopathy in patients with muscle symptoms.
Outcomes in 45 patients with statin-associated myopathy.
TLDR
Patients with statin-associated myopathy experienced full resolution of muscle pain on cessation of statin therapy, and were more likely to be taking concomitant medications known to increase the risk of statins without recurrent symptoms.
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
TLDR
Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin, pravastsatin, and simvastsatin; combined statin-fibrate use increased risk, especially in older patients with diabetes mellitus.
Statin safety: a systematic review.
...
1
2
3
4
...